ANVS · Annovis Bio, Inc. · Insider Trading

The stock option was granted in consideration for consulting services that reporting person will perform for the Company.

The stock option shall vest in quarterly increments, based upon the services performed by the reporting person under the related Consulting Agreement.

Represents charitable gifts donated by the reporting person. No proceeds were received by the reporting person.

Represents charitable gifts donated by the reporting person. No proceeds were received by the reporting person.

Represents charitable gifts donated by the reporting person. No proceeds were received by the reporting person.

The stock option was granted in consideration for consulting services that reporting person will perform for the Company.

The stock option shall vest immediately upon grant date.

This amendment is being filed solely to reverse the previously reported purchase on the original form 4 filed on November 21, 2023 (the "Original Form 4"). Such purchase was rescinded by the registrant and the reporting person on November 22, 2023.

This amendment is being filed solely to reverse the previously reported purchase on the original form 4 filed on November 21, 2023 (the "Original Form 4"). Such purchase was rescinded by the registrant and the reporting person on November 22, 2023.

The shares are held in a family trust formed by the reporting person and the reporting person has voting and investment power over such shares.

On June 12, 2024, stockholders of Annovis Bio, Inc. approved an amendment to the 2019 Equity Incentive Plan to increase the number of shares issuable thereunder from 2,000,000 to 3,000,000. 50% of the stock option grant listed was contingent upon the approval of such amendment and would have been forfeited if the amendment had not been approved.

Stock option will vest in eight consecutive quarterly installments of 31,500 shares each on the 17th day of February, May, August and November of each year, continuing through November 17, 2025.

The stock option was granted in lieu of cash payment for 2023 fiscal year bonus. 100% of the stock option grant listed was also contingent upon the aforementioned amendment to the 2019 Equity Incentive Plan to increase the number of issuable shares from 2,000,000 to 3,000,000. It would have been forfeited if the amendment had not been approved.

The stock option shall vest immediately.

On June 12, 2024, stockholders of Annovis Bio, Inc. approved an amendment to the 2019 Equity Incentive Plan to increase the number of shares issuable thereunder from 2,000,000 to 3,000,000. 50% of the stock option grant listed was contingent upon the approval of such amendment and would have been forfeited if the amendment had not been approved.

The stock option shall vest immediately upon grant date.

On June 12, 2024, stockholders of Annovis Bio, Inc. approved an amendment to the 2019 Equity Incentive Plan to increase the number of shares issuable thereunder from 2,000,000 to 3,000,000. 50% of the stock option grant listed was contingent upon the approval of such amendment and would have been forfeited if the amendment had not been approved.

The stock option shall vest immediately upon grant date.

On June 12, 2024, stockholders of Annovis Bio, Inc. ("the Company") approved an amendment to the 2019 Equity Incentive Plan to increase the number of shares issuable thereunder from 2,000,000 to 3,000,000. 50% of the stock option grant listed was contingent upon the approval of such amendment and would have been forfeited if the amendment had not been approved.

The stock option shall vest immediately upon grant date.

On June 12, 2024, stockholders of Annovis Bio, Inc. approved an amendment to the 2019 Equity Incentive Plan to increase the number of shares issuable thereunder from 2,000,000 to 3,000,000. 50% of the stock option grant listed was contingent upon the approval of such amendment and would have been forfeited if the amendment had not been approved.

The stock option shall vest immediately upon grant date.

The shares are held in a family trust formed by the reporting person and the reporting person has voting and investment power over such shares.